Jan Petr1, Ivan Platzek2, Annekatrin Seidlitz3, Henri J M M Mutsaerts4, Frank Hofheinz5, Georg Schramm6, Jens Maus5, Bettina Beuthien-Baumann7, Mechthild Krause8, Jörg van den Hoff7. 1. Helmholtz-Zentrum Dresden-Rossendorf, PET Center, Institute of Radiopharmaceutical Cancer Research, Dresden, Germany. Electronic address: j.petr@hzdr.de. 2. Department of Radiology, University Hospital Carl Gustav Carus, Technical University Dresden, Germany. 3. Department of Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technical University Dresden, Germany; OncoRay - National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technical University Dresden, Germany; German Cancer Consortium (DKTK) Dresden and German Cancer Research Center (DKFZ) Heidelberg, Germany. 4. Brain Sciences Research Program, Sunnybrook Research Institute, Toronto, Canada. 5. Helmholtz-Zentrum Dresden-Rossendorf, PET Center, Institute of Radiopharmaceutical Cancer Research, Dresden, Germany. 6. Helmholtz-Zentrum Dresden-Rossendorf, PET Center, Institute of Radiopharmaceutical Cancer Research, Dresden, Germany; Department of Imaging and Pathology, Katholieke Universiteit Leuven, Belgium. 7. Helmholtz-Zentrum Dresden-Rossendorf, PET Center, Institute of Radiopharmaceutical Cancer Research, Dresden, Germany; Department of Nuclear Medicine, University Hospital Carl Gustav Carus, Technical University Dresden, Germany. 8. Department of Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technical University Dresden, Germany; OncoRay - National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technical University Dresden, Germany; German Cancer Consortium (DKTK) Dresden and German Cancer Research Center (DKFZ) Heidelberg, Germany; Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiooncology, Germany.
Abstract
BACKGROUND AND PURPOSE: To provide a systematic measure of changes of brain perfusion in healthy tissue following a fractionated radiotherapy of brain tumors. MATERIALS AND METHODS: Perfusion was assessed before and after radiochemotherapy using arterial spin labeling in a group of 24 patients (mean age 54.3 ± 14.1 years) with glioblastoma multiforme. Mean relative perfusion change in gray matter in the hemisphere contralateral to the tumor was obtained for the whole hemisphere and also for six regions created by thresholding the individual dose maps at 10 Gy steps. RESULTS: A significant decrease of perfusion of -9.8 ± 20.9% (p=0.032) compared to the pre-treatment baseline was observed 3 months after the end of radiotherapy. The decrease was more pronounced for high-dose regions above 50 Gy (-16.8 ± 21.0%, p=0.0014) than for low-dose regions below 10 Gy (-2.3 ± 20.0%, p=0.54). No further significant decrease compared to the post-treatment baseline was observed 6 months (-0.4 ± 18.4%, p=0.94) and 9 months (2.0 ± 15.4%, p=0.74) after the end of radiotherapy. CONCLUSIONS: Perfusion decreased significantly during the course of radiochemotherapy. The decrease was higher in regions receiving a higher dose of radiation. This suggests that the perfusion decrease is at least partly caused by radiotherapy. Our results suggest that the detrimental effects of radiochemotherapy on perfusion occur early rather than later.
BACKGROUND AND PURPOSE: To provide a systematic measure of changes of brain perfusion in healthy tissue following a fractionated radiotherapy of brain tumors. MATERIALS AND METHODS: Perfusion was assessed before and after radiochemotherapy using arterial spin labeling in a group of 24 patients (mean age 54.3 ± 14.1 years) with glioblastoma multiforme. Mean relative perfusion change in gray matter in the hemisphere contralateral to the tumor was obtained for the whole hemisphere and also for six regions created by thresholding the individual dose maps at 10 Gy steps. RESULTS: A significant decrease of perfusion of -9.8 ± 20.9% (p=0.032) compared to the pre-treatment baseline was observed 3 months after the end of radiotherapy. The decrease was more pronounced for high-dose regions above 50 Gy (-16.8 ± 21.0%, p=0.0014) than for low-dose regions below 10 Gy (-2.3 ± 20.0%, p=0.54). No further significant decrease compared to the post-treatment baseline was observed 6 months (-0.4 ± 18.4%, p=0.94) and 9 months (2.0 ± 15.4%, p=0.74) after the end of radiotherapy. CONCLUSIONS: Perfusion decreased significantly during the course of radiochemotherapy. The decrease was higher in regions receiving a higher dose of radiation. This suggests that the perfusion decrease is at least partly caused by radiotherapy. Our results suggest that the detrimental effects of radiochemotherapy on perfusion occur early rather than later.
Authors: Line Brennhaug Nilsen; Ingrid Digernes; Endre Grøvik; Cathrine Saxhaug; Anna Latysheva; Oliver Geier; Birger Breivik; Dag Ottar Sætre; Kari Dolven Jacobsen; Åslaug Helland; Kyrre Eeg Emblem Journal: Neurooncol Adv Date: 2020-02-28